CLS closed Tuesday at CAD 431.98, down 8.4% on the day — a sharp move that sits in the context of a broader EMS sector selloff, not an isolated story. The real intrigue this week is that CEO Rob Mionis was selling heavily just days before the slide.
The insider picture is the lead here. Mionis sold shares across multiple tranches on August 5 and again on August 13 — totalling roughly CAD $10M+ in combined proceeds at prices ranging from C$360 to C$375. Those sales went through before Tuesday's drop to CAD 432 (note the stock was trading on the TSX, values are CAD). The 90-day insider net is positive at 91,201 shares, suggesting earlier accumulation, but the recent cluster of CEO sells is conspicuous timing. Trade significance scores on each transaction came in at just 2 out of 10, suggesting these may be part of a pre-arranged plan rather than a discretionary bearish call — but the scale, more than $10M across two dates, is worth flagging regardless.
The lending market tells a completely relaxed story, which is the sharpest contrast in this note. Availability is about as loose as it gets — over 9,500% — meaning there are roughly 95 shares available to borrow for every one already lent out. Short interest barely registers at 1% of free float, and that level has been broadly stable for weeks. Cost to borrow has collapsed over the past month, down 24%, and now sits near 0.26%. None of this points to any meaningful short-side conviction. Bears are not loading up. The lending market is wide open and nobody is rushing through the door.
The sector context explains much of Tuesday's damage. Close peers all fell hard on the day: JBL dropped 8.5%, PLXS fell 7.7%, COHR lost 12.8%, and FN led the carnage at -19.4%. CLS was roughly in line with the group, suggesting the move was macro or sector-driven rather than a company-specific event. SNX was the outlier, off just 1.5% on the day and up 2.3% on the week — a divergence worth noting if sector rotation is the frame.
The fundamental picture still carries real positives. EPS momentum ranks in the 92nd percentile over 30 days and 87th over 90 days — among the strongest in the universe. The ORTEX short score is a low 26.9, consistent with the undemanding borrow conditions. EV/EBITDA has compressed roughly 3.6 points over the past 30 days to 13.7x, while the PE has pulled back around 3 points to 20.4x — the stock has de-rated meaningfully into this week's drop. On valuation alone, the setup looks less stretched than it did a month ago. FMR (Fidelity) remains the largest holder at 6.85% of shares, adding nearly 913,000 shares in the most recent reported quarter. Franklin Templeton and BMO Asset Management were also adding into Q2. Institutional support is not crumbling.
Next quarter's earnings are scheduled for October 28. With the stock having just repriced 8% lower in a single session alongside the broader EMS complex, the October print — and whatever guidance Celestica gives on hyperscaler demand and its Advanced Technology Solutions segment — becomes the next meaningful test of whether Tuesday's move was a sector flush or the start of something more.
See the live data behind this article on ORTEX.
Open CLS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
